Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059995 · ClinicalTrials.gov registry record · Phase 1
MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00059995: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00059995 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00059995, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as MDX-060 can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of MDX-060 monoclonal antibody in treating patients who have refractory or relapsed lymphoma.
Interventions
- BIOLOGICAL iratumumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-01 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
What the finished NCT00059995 record still lists
NCT00059995 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which iratumumab is the first listed.
NCT00059995 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00059995 about?
NCT00059995 is a clinical study titled "MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma". RATIONALE: Monoclonal antibodies such as MDX-060 can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of MDX-060 monoclonal antibody in treating patients who have refractory or re...
What is the current status of trial NCT00059995?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-01. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00059995?
The interventions under investigation include: iratumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00059995?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia